The Leading Community for Trusted Peptide Research & Insights
Research summaries, dosing protocols, and community reports for peptides. Built on clinical data and real-world experiences.
BPC-157 and TB-500 are the two most discussed healing peptides in research communities. While both are studied for tissue repair and recovery, they work through fundamentally different mechanisms — BPC-157 primarily modulates growth factor expression and promotes angiogenesis, while TB-500 (a fragment of Thymosin Beta-4) promotes cell migration and reduces inflammation at the cellular level.
This comparison breaks down the key differences in mechanism, administration, evidence quality, and how researchers approach each peptide for different injury types.
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Category | Body Protection Compound | Thymosin Beta-4 Fragment |
| Primary Mechanism | Angiogenesis, growth factor modulation, nitric oxide pathway | Actin sequestration, cell migration, anti-inflammatory |
| Administration Route | Subcutaneous, oral (partial bioavailability) | Subcutaneous, intramuscular |
| Research Dosing | 200-500 mcg/day (subcutaneous) | 2-5 mg twice weekly |
| Evidence Level | 100+ preclinical studies, limited human data | Moderate preclinical data, fewer total studies |
| Key Benefit | Gut healing, tendon/ligament repair, systemic protection | Muscle repair, wound healing, cardiac tissue repair |
| Side Effects | Minimal reported in studies (nausea rare) | Head rush, lethargy (transient) |
| Oral Availability | Partial — studied orally for gut conditions | No — injection required |
Body Protection Compound-157 (BPC-157) is a 15-amino-acid fragment originally isolated from proteins in the human stomach lining. Most evidence comes from animal studies exploring wound healing, tendon repair, and gut health applications.
TB-500 is a synthetic peptide fragment derived from Thymosin Beta-4, a naturally occurring protein involved in tissue repair. Research focuses on wound healing, tissue regeneration, and reducing inflammation.
BPC-157 and TB-500 are commonly researched together and represent the most popular healing peptide stack. Their mechanisms are complementary: BPC-157 promotes blood vessel formation and growth factor signaling, while TB-500 drives cell migration to injury sites and modulates inflammation. Preclinical evidence suggests the combination may produce synergistic effects on tissue repair, though direct head-to-head stacking studies are limited.
BPC-157 has more published research specifically on tendon healing, including studies showing accelerated Achilles tendon repair and improved collagen organization. TB-500 has broader wound-healing data but less tendon-specific research. Many researchers studying tendon injuries prioritize BPC-157 or use both together.
Yes, BPC-157 and TB-500 are frequently researched together. Their complementary mechanisms — BPC-157's angiogenic and growth factor effects combined with TB-500's cell migration and anti-inflammatory properties — make them a logical pairing for tissue repair research.
BPC-157 has significantly more published research, with over 100 preclinical studies covering a wide range of tissue types. TB-500 (Thymosin Beta-4) also has substantial research, particularly in wound healing and cardiac repair, but the total volume of published studies is smaller. Neither has robust Phase 3 clinical trial data in humans.